摘要
目的观察糜酶在糖尿病大鼠肾损害过程中的作用。方法将大鼠随机分为正常对照(NC)组、DM组、应用糜酶抑制剂的DM(Chy-I)组,Chy-I组予糜酶抑制剂治疗12周。结果与DM组比较,Chy-I组UAlb/Cr明显降低[(0.34±0.15)vs(1.38±0.95)g/μmol,P<0.05],高胆固醇血症得到显著改善[(1.95±0.31)vs(2.31±0.30)mmol/L,P<0.05],纤维粘连蛋白(FN)和Ⅳ型胶原(ColⅣ)基因表达下调(0.53 vs 0.71,P<0.01;0.48 vs 0.58,P<0.01)。结论糜酶参与了大鼠DN的发生发展。
Objective To investigate the effect of chymase on the development of renal lesion in diabetic rats. Methods The rats were randomized into control group（NC group）, DM group, and Chy-I （chymase inhibitor） treatment group. The Chy-I group was treated with chymase inhibitor for 12 weeks. Results Compared with the DM group, the level of urinary albumin/creatinin ratio （UAlb/Cr） was decreased in the Chy-I group [（0.34 ± 0.15） vs （1.38 ±0.95） g/μmol, P〈0.05], the hypercholesterinemia was significantly improved [ （1.95 ±0.31） vs （2.31±0.30） mmol/L, P〈0.05], and the gene expression of fibronection （FN） and collagen Ⅳ （ColⅣ） was decreased （0.53 vs 0. 71, P〈0. 01; 0.48 vs 0. 58, P〈0. 01）. Conclusion In the diabetic rats, chymase plays an important role in the development of renal fibrosis.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2012年第11期867-869,共3页
Chinese Journal of Diabetes
基金
首都医科大学基础-临床科研合作基金(11JL41)
关键词
糜酶
糖尿病肾病
纤维化
细胞外基质
Chymase
Diabetic nephropathy
Fibrosis
Extracellular matrix
